Payment overview · 2025
General Payments
$196.28
11 reported records · 8 companies
Healthcare provider profile · identity verified
Shane Michael Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOLDREGE, NE · NPI 1184705980
Verified facts
What the public records show
CMS Open Payments records show Shane Michael Smith, M.D. received $196.28 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.17 | 18.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.25 | 17.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.47 | 16.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.74 | 14.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.87 | 10.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.27 | 8.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.82 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.69 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $196.28 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.17 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.25 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.47 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.74 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 568 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 82 |
| Omeprazole | Omeprazole | 362 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 77 |
| Potassium Chloride | Potassium Chloride | 293 | 63 |
| Lisinopril | Lisinopril | 292 | 59 |
| Losartan Potassium | Losartan Potassium | 238 | 50 |
| Glipizide Er | Glipizide | 226 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 51 |
| Metformin Hcl Er | Metformin Hcl | 206 | 38 |
| Furosemide | Furosemide | 205 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 38 |
| Gabapentin | Gabapentin | 201 | 33 |
| Alendronate Sodium | Alendronate Sodium | 191 | 41 |
| Sertraline Hcl | Sertraline Hcl | 174 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 39 |
| Warfarin Sodium | Warfarin Sodium | 139 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 28 |
| Ozempic | Semaglutide | 125 | 15 |
| Meloxicam | Meloxicam | 124 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 21 |
| Tramadol Hcl | Tramadol Hcl | 111 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 12 |
| Finasteride | Finasteride | 104 | 25 |
| Allopurinol | Allopurinol | 103 | 18 |
| Eliquis | Apixaban | 100 | 16 |
| Metformin Hcl | Metformin Hcl | 98 | 18 |
| Xarelto | Rivaroxaban | 98 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 18 |
| Simvastatin | Simvastatin | 84 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | suppressed |
| Azithromycin | Azithromycin | 77 | 59 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | suppressed |
| Jardiance | Empagliflozin | 73 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 16 |
| Celecoxib | Celecoxib | 65 | 12 |
| Montelukast Sodium | Montelukast Sodium | 61 | 11 |
| Spironolactone | Spironolactone | 61 | 16 |
| Lorazepam | Lorazepam | 59 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 57 | suppressed |
| Fentanyl | Fentanyl | 57 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 42 |
| Cefdinir | Cefdinir | 48 | 43 |
| Carvedilol | Carvedilol | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 41 | suppressed |
| Prednisone | Prednisone | 40 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Cephalexin | Cephalexin | 37 | 33 |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 31 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 13 |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | 13 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 15 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $196.28 · 11 records | PFIZER INC. | ABRYSVO, BodyGuardian, COMIRNATY, EVENITY, Kerendia, LEQVIO, Ozempic, PREVNAR 20, Rybelsus, Veozah, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error